These patients rather benefit from novel treatment approaches in CLL such as inhibitors of the B-cell receptor pathway (BCRi), e.g. the BTK inhibitor ibrutinib [12] and the PI3Kδ inhibitor idelalisib [13], or antiapoptotic proteins, e.g. the Bcl-2 inhibitor venetoclax [14]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.